Published in Clin Sci Mol Med Suppl on December 01, 1976
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther (1973) 2.14
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos (1979) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. J Clin Invest (1973) 1.10
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol (1981) 1.08
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Spironolactone. Am Heart J (1978) 1.05
[On the metabolism of antipyrine (phenazone) in man (author's transl)]. Arzneimittelforschung (1978) 1.04
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol (1987) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
The mechanism of uptake of norepinephrine. Pharmacol Rev (1966) 1.01
Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther (1981) 0.99
Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol (1987) 0.99
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Report of a workshop on fixed-ratio drug combinations. Eur J Clin Pharmacol (1975) 0.97
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. Eur J Clin Pharmacol (1981) 0.96
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Sensitive high-performance liquid chromatographic assay for the determination of eugenol in body fluids. J Chromatogr (1990) 0.95
HPLC determination of antipyrine metabolites. Pharmacology (1981) 0.95
Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol (1997) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Single- and multiple-dose kinetics of intravenous digoxin. Clin Pharmacol Ther (1980) 0.93
The metabolism of tramadol by human liver microsomes. Clin Investig (1992) 0.93
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
[Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)]. Arzneimittelforschung (1977) 0.90
Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1980) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Impairment of digoxin clearance by coadministration of quinidine. J Clin Pharmacol (1981) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Dose-independent pharmacokinetics of digoxin in humans. Am Heart J (1978) 0.86
Disposition of valproic acid in man. Eur J Clin Pharmacol (1977) 0.85
Proceedings: N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.85
Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol (1979) 0.85
High-performance liquid chromatographic assay for the simultaneous determination of tramadol and its metabolites in microsomal fractions of human liver. J Chromatogr B Biomed Appl (1996) 0.84
[Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)]. Klin Wochenschr (1982) 0.84
Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther (1987) 0.83
Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clin Pharmacol Ther (1982) 0.83
Noninteraction of digitoxin and quinidine. N Engl J Med (1980) 0.83
[Purification and characterization of a 3'-phosphoadenylylsulfate: steroid sulfotransferase from human liver]. Biochim Biophys Acta (1970) 0.83
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J (1984) 0.82
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
[Drugs interacting with coumarine oral anticoagulants (author's transl)]. Klin Wochenschr (1973) 0.82
Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J (1980) 0.82
Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J Chromatogr (1983) 0.82
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat (2004) 0.82
Absorption of digoxin from the distal parts of the intestine in man. Eur J Clin Pharmacol (1975) 0.81
Autoimmune neutropenia due to NA1 specific antibodies in primary biliary cirrhosis. Br J Haematol (1991) 0.81
[Determination of digoxin and digitoxin in the blood and their clinical significance]. Klin Wochenschr (1973) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Ultrasound-guided emergency endoscopic retrograde biliary drainage without radiography. Endoscopy (1997) 0.81
Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr (1985) 0.80
Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clin Pharmacol Ther (1979) 0.80
Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol (1988) 0.80
[Incidence of catechol-O-methyltransferase in human erythrocytes]. Arch Int Pharmacodyn Ther (1973) 0.79
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Cancer Epidemiol Biomarkers Prev (1999) 0.79
Diazepam kinetics in relation to age and sex. Pharmacology (1981) 0.79
In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol (1985) 0.79
Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klin Wochenschr (1985) 0.79
Simple fluorometric method for estimating practolol (1-(4-aminophenoxy)-3-isopropylaminopropan-2-0l) in blood and urine. Clin Chem (1972) 0.79